SG11201404834XA - N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt - Google Patents
N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate saltInfo
- Publication number
- SG11201404834XA SG11201404834XA SG11201404834XA SG11201404834XA SG11201404834XA SG 11201404834X A SG11201404834X A SG 11201404834XA SG 11201404834X A SG11201404834X A SG 11201404834XA SG 11201404834X A SG11201404834X A SG 11201404834XA SG 11201404834X A SG11201404834X A SG 11201404834XA
- Authority
- SG
- Singapore
- Prior art keywords
- pyridin
- cyclohepta
- imidazo
- difluorophenyl
- tetrahydro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603598P | 2012-02-27 | 2012-02-27 | |
| PCT/US2013/027648 WO2013130402A1 (en) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404834XA true SG11201404834XA (en) | 2014-09-26 |
Family
ID=47844498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404834XA SG11201404834XA (en) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8759372B2 (lt) |
| EP (2) | EP3254681B1 (lt) |
| JP (2) | JP6208154B2 (lt) |
| KR (2) | KR102076118B1 (lt) |
| CN (1) | CN104136437B (lt) |
| AU (1) | AU2013226361B2 (lt) |
| BR (1) | BR112014021032B1 (lt) |
| CA (1) | CA2865585C (lt) |
| CY (2) | CY1119448T1 (lt) |
| DK (2) | DK2820016T3 (lt) |
| EA (1) | EA025358B1 (lt) |
| ES (2) | ES2746031T3 (lt) |
| HK (1) | HK1248111B (lt) |
| HR (2) | HRP20171620T1 (lt) |
| HU (2) | HUE047050T2 (lt) |
| IL (1) | IL234272B (lt) |
| LT (2) | LT3254681T (lt) |
| MX (1) | MX352171B (lt) |
| NO (1) | NO2935439T3 (lt) |
| PL (2) | PL3254681T3 (lt) |
| PT (2) | PT2820016T (lt) |
| RS (2) | RS56556B1 (lt) |
| SG (1) | SG11201404834XA (lt) |
| SI (2) | SI2820016T1 (lt) |
| WO (1) | WO2013130402A1 (lt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3272769B1 (en) | 2012-01-26 | 2020-06-17 | Christopher J. Soares | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
| SI2820016T1 (sl) * | 2012-02-27 | 2017-11-30 | Bristol-Myers Squibb Company | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h- ciklohepta (b)piridin-9-il-4-(2-okso-2, 3-dihidro-1h-imidazo(4,5-b) piridin-1-il) piperidin-1-karboksilat, hemisulfatna sol |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| UA124966C2 (uk) | 2015-03-06 | 2021-12-22 | Атеа Фармасеутікалс, Інк. | <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ |
| ES2965087T3 (es) * | 2016-09-02 | 2024-04-10 | Soares Christopher J | Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma |
| EP3865136A1 (en) | 2016-09-07 | 2021-08-18 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for corona virus treatment |
| KR20230151050A (ko) | 2017-02-01 | 2023-10-31 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
| SG11202009199YA (en) * | 2018-03-25 | 2020-10-29 | Biohaven Pharm Holding Co Ltd | Rimegepant for cgrp related disorders |
| TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
| AU2020210024A1 (en) * | 2019-01-20 | 2021-07-01 | Biohaven Pharmaceutical Holding Company Ltd. | CGRP antagonists for treating migraine breakthrough |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| EP4301362A1 (en) | 2021-03-02 | 2024-01-10 | CGRP Diagnostics GmbH | Treatment and/or reduction of occurrence of migraine |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| AR126954A1 (es) * | 2021-09-02 | 2023-12-06 | Biohaven Pharm Holding Co Ltd | Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| CN116554164A (zh) * | 2022-01-27 | 2023-08-08 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
| WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA24500A1 (fr) * | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| EP1726590A4 (en) | 2004-03-05 | 2009-07-15 | Banyu Pharma Co Ltd | D RIV CYCLOALKANOPYRIDINE |
| JP4913061B2 (ja) | 2004-10-13 | 2012-04-11 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体拮抗薬 |
| EP1804919B1 (en) | 2004-10-22 | 2011-03-30 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
| CA2649158A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of pyridine heterocycle cgrp antagonist intermediate |
| DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
| US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| SI2820016T1 (sl) * | 2012-02-27 | 2017-11-30 | Bristol-Myers Squibb Company | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h- ciklohepta (b)piridin-9-il-4-(2-okso-2, 3-dihidro-1h-imidazo(4,5-b) piridin-1-il) piperidin-1-karboksilat, hemisulfatna sol |
-
2013
- 2013-02-25 SI SI201330759T patent/SI2820016T1/sl unknown
- 2013-02-25 MX MX2014009544A patent/MX352171B/es active IP Right Grant
- 2013-02-25 ES ES17180587T patent/ES2746031T3/es active Active
- 2013-02-25 EA EA201491585A patent/EA025358B1/ru not_active IP Right Cessation
- 2013-02-25 AU AU2013226361A patent/AU2013226361B2/en active Active
- 2013-02-25 LT LTEP17180587.2T patent/LT3254681T/lt unknown
- 2013-02-25 RS RS20171092A patent/RS56556B1/sr unknown
- 2013-02-25 KR KR1020147023856A patent/KR102076118B1/ko active IP Right Grant
- 2013-02-25 CN CN201380011305.6A patent/CN104136437B/zh active Active
- 2013-02-25 RS RSP20191191 patent/RS59295B1/sr unknown
- 2013-02-25 WO PCT/US2013/027648 patent/WO2013130402A1/en active Application Filing
- 2013-02-25 PT PT137086039T patent/PT2820016T/pt unknown
- 2013-02-25 SI SI201331560T patent/SI3254681T1/sl unknown
- 2013-02-25 DK DK13708603.9T patent/DK2820016T3/da active
- 2013-02-25 EP EP17180587.2A patent/EP3254681B1/en active Active
- 2013-02-25 HU HUE17180587A patent/HUE047050T2/hu unknown
- 2013-02-25 CA CA2865585A patent/CA2865585C/en active Active
- 2013-02-25 LT LTEP13708603.9T patent/LT2820016T/lt unknown
- 2013-02-25 SG SG11201404834XA patent/SG11201404834XA/en unknown
- 2013-02-25 PT PT171805872T patent/PT3254681T/pt unknown
- 2013-02-25 BR BR112014021032-2A patent/BR112014021032B1/pt active IP Right Grant
- 2013-02-25 PL PL17180587T patent/PL3254681T3/pl unknown
- 2013-02-25 ES ES13708603.9T patent/ES2642737T3/es active Active
- 2013-02-25 DK DK17180587.2T patent/DK3254681T3/da active
- 2013-02-25 HU HUE13708603A patent/HUE034936T2/hu unknown
- 2013-02-25 US US13/775,528 patent/US8759372B2/en active Active
- 2013-02-25 EP EP13708603.9A patent/EP2820016B1/en active Active
- 2013-02-25 PL PL13708603T patent/PL2820016T3/pl unknown
- 2013-02-25 KR KR1020207003401A patent/KR102220969B1/ko active IP Right Grant
- 2013-02-25 JP JP2014558927A patent/JP6208154B2/ja active Active
- 2013-12-10 NO NO13811338A patent/NO2935439T3/no unknown
-
2014
- 2014-08-24 IL IL234272A patent/IL234272B/en active IP Right Grant
-
2017
- 2017-09-06 JP JP2017171358A patent/JP6476253B2/ja active Active
- 2017-10-10 CY CY20171101052T patent/CY1119448T1/el unknown
- 2017-10-25 HR HRP20171620TT patent/HRP20171620T1/hr unknown
-
2018
- 2018-06-12 HK HK18107632.9A patent/HK1248111B/zh unknown
-
2019
- 2019-09-11 CY CY20191100951T patent/CY1122121T1/el unknown
- 2019-09-16 HR HRP20191655 patent/HRP20191655T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248111B (zh) | N-(5s，6s，9r)-4-(2-氧代-2，3-二氫-1h-咪唑並[4，5-b]吡啶-1-基)呱啶-1-羧酸5-氨基-6-(2，3-二氟苯基)-6，7，8，9-四氫-5h-環庚三烯並[b]吡啶-9-基酯半硫酸鹽 | |
| ZA201906379B (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| HK1226394A1 (zh) | 7-氮雜吲哚衍生物 | |
| HK1217488A1 (zh) | -二氨基- -氟苄基 -吡唑并 吡啶- -基 嘧啶- -基}甲基氨基甲酸甲酯的形式 | |
| EP2931722A4 (en) | SUBSTITUTED 1H-PYRROLO- [2,3-B] PYRIDINE AND 1H-PYRAZOLO- [3,4-B] PYRIDINE DERIVATIVES AS SALT-INDUCIBLE KINASE-2 (SIK2) INHIBITORS | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| ZA201409299B (en) | Risperidone or paliperidone implant formulation | |
| PL2609082T3 (pl) | Imidazo[4,5-C]chinoliny jako inhibitory DNA-PK | |
| HK1200447A1 (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors 1h-[2,3-b] | |
| IL228820A0 (en) | 7-(heteroaryl-amino)-9,8,7,6-tetrahydropyrido[2,1-a]indole acetic acid derivatives and their use as prostaglandin 2d receptor modulators |